Navigation Links
Significant funding for type 1 diabetes research
Date:1/25/2008

Researchers from the Peninsula Medical School in the South West of England have received funding of $480,000 from the Juvenile Diabetes Research Foundation, the worlds largest charitable funder of type 1 diabetes research, to study a unique collection of pathology samples from people who died soon after diagnosis of Type 1 diabetes.

The aim of the research, which will use around 70 samples collected by Dr Alan Foulis, a pathologist from Glasgow, is to identify the triggers that cause Type 1 diabetes and the sequence of events that lead to the first symptoms.

Type 1 diabetes develops when the body is unable to produce its own insulin. Type 1 diabetes is an autoimmune disease which strikes in childhood, adolescence, or adulthood, but lasts a lifetime. It accounts for between five per cent and 15 per cent of all people with diabetes. It also requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.

The research will cover new ground by seeking to identify what it is that initiates the process in man, and will consider the possibility that Type 1 diabetes could be triggered by environmental factors such as certain viruses. It will also map the progression of the disease in relation to the immune system and will seek to establish if there is a defined sequence of events, and why this is so.

Professor Noel Morgan from the Peninsula Medical School commented: This is very exciting research which can be expected to provide new insights into the causes of diabetes. If we can identify the triggers that set Type 1 diabetes into motion, and the sequence of events that lead to symptoms, there is potential for the development of therapies to prevent or halt the disease.

He added: The process can st
'/>"/>

Contact: Andrew Gould
media@pr-works.co.uk
01-392-686-107
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study finds significant differences in protocols hospitals use to determine brain death
2. Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers
3. Despite efforts, significant racial disparities in cancer therapy still exist
4. Tonsillectomy significantly improves quality of life in adult and pediatric patients
5. Significant changes in plastic surgery expected in 2008
6. Adult ADHD significantly impacts on social, financial and personal aspects of life
7. Recent studies confirm significant underuse of colorectal cancer screening
8. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
9. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
10. A Major Gift of Art and History: U-M Receives 45 Significant Medical Paintings From Pfizer
11. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...epresentatives from the fitness,company Burn Mach... Shriners,Hospitals for Children in Chicago last ...nique, cause; The Burn Machine donated more than $...ent to the first ever Shriners,Wheelchair Bodybui...com/cgi-bin/prnh/20081203/CLW007 ) , "We k...
(Date:12/2/2008)...ersity, The Brigham and Women,s Hospital (Boston),...has found a new drug with the potential to allevia...k. , Dr Shantha Rajaratnam from Monash Universi...gical Medicine said tasimelteon, a drug which acts...ighly effective treatment for circadian rhythm sle...
(Date:12/2/2008)... Reminder, the nation,s leading,comprehensive pat... industry,technology today at Javits Center in Ne...ng and distributing video testimonials can be used... popular platforms such as YouTube, Google,Videos...with an effective,business strategy for increasin...
(Date:12/2/2008)... enterprise software and online services veteran i...scribers of Yugma,s instant web conferencing solut...RWEB) December 2, 2008 -- Yugma , the leading web... collaborate instantly using the Internet, announc...utive Officer. , , ,Vas has more than 20 years of ...
Breaking Medicine News(10 mins):Health News:Burn Machine Speed Bag Knocks 'em Out at Shriners Wheelchair Bodybuilding Camp 2Health News:New medication brings hope of jet lag cure 2Health News:Doctors Go Viral: vSling Video Testimonial Tool Offers Doctors Access to New Channels for Acquiring Patients 2Health News:Doctors Go Viral: vSling Video Testimonial Tool Offers Doctors Access to New Channels for Acquiring Patients 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3
...onmental Protection announced today that aerial sp...mosquito larvae in Philadelphia have been resched...oLex CG, which is not a chemical pesticide, but is...that targets mosquito and black fly larvae when ad...
...known as integrin alpha 7 (integrin 7) lead to unc...cer, report researchers at the University of Pitt...ed today in the Journal of the National Cancer Ins...a7 represents an important new target for cancer t...
...5N1 strain of bird flu has been detected among pou...n capital, officials said Wednesday. The virus w... Sungai Buloh area of Selangor state, said Kamarud...se control section at the Department of Veterinary...
...to stop feeling hungry, for researchers have devel...rmone which makes people feel full . Researchers d...aturally occurring hormone that is excreted during...he brain called MC4R. When the bodys need for food...
Other Medicine News:Health News:Rescheduled: Aerial Mosquito Treatment for Philadelphia 2Health News:A New Target for Cancer Therapy-Integrin Alpha7 Molecule 2Health News:A New Target for Cancer Therapy-Integrin Alpha7 Molecule 3Health News:A New Target for Cancer Therapy-Integrin Alpha7 Molecule 4Health News:Bird Flu Reappears in Malaysia 2
(Date:11/28/2008)...re/ -- German biotech company,Partec is expanding...ng and,AIDS patient follow-up diagnostics for dev... 2.5 million patient tests have been performed wit...low" system, supporting already,more than 1 milli...n of the,Partec innovation, the average cost of E...
(Date:11/26/2008)...d intelligent clinical applications take workflow ... , CHICAGO, Ill., Nov. 26 /PRNewswire-FirstCall...thcare ) highlights the ACUSON S2000(TM) Automate...rst multi-use, automated volume breast ultrasound ... Meeting of the Radiological Society of North Amer...
(Date:11/25/2008)...nding statin use broadly in wake of AHA-presented ...wswire/ -- JUPITER, a clinical trial suggesting ro...althy patients with elevated CRP, should not promp...to a national poll directed at health professional... poll conducted by medical news site MedPage Today...
(Date:11/25/2008)...ssess Survival of Patients Receiving Litx versus S...ellular Carcinoma , , BELLEVUE, Wash., Nov....(LSO) today announced the completion of enrollment...ion Therapy(TM) (Litx(TM)) as a treatment for unre...n as hepatoma or primary liver cancer. , , ...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Chemical liberated by leaky gut may allow HIV to infect the brain Einstein scientists find 25520 1Chemical liberated by leaky gut may allow HIV to infect the brain Einstein scientists find 25520 2Chemical liberated by leaky gut may allow HIV to infect the brain Einstein scientists find 25520 3Chemical liberated by leaky gut may allow HIV to infect the brain Einstein scientists find 25520 4Researchers study facial structures brain abnormalities to reveal formula for detection of autism 4511 1Researchers study facial structures brain abnormalities to reveal formula for detection of autism 4511 2Signals from the Atlantic salmon highway 4508 1Signals from the Atlantic salmon highway 4508 2Signals from the Atlantic salmon highway 4508 3Signals from the Atlantic salmon highway 4508 4Medco Announces Research Collaboration with FDA Focused on Personalized Medicine 25512 1Medco Announces Research Collaboration with FDA Focused on Personalized Medicine 25512 2Medco Announces Research Collaboration with FDA Focused on Personalized Medicine 25512 3Medco Announces Research Collaboration with FDA Focused on Personalized Medicine 25512 4
... the Journal of Clinical Oncology -, NEW YORK, Jul...a,Phase II study - which will be published in the ...ncology (JCO) and are now,available as an Early Re...www.jco.org/">www.jco.org - demonstrate that,ixab...ional,compound, has activity in patients with meta...
... TMC125, an Investigational NNRTI,from Tibotec, YA...m two,ongoing Phase 3 studies (DUET-1 and DUET-2) ...h documented non-nucleoside reverse,transcriptase ...stance reached an undetectable viral load (defined...V-1 RNA copies/mL) with,TMC125 (etravirine), Tibot...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle.
Fixed smooth rod which slides on skin. Designated most popular model or size.
For use with N4096 R, N4097 R and N4098 R. 18 mm wide x 167 mm long. Ten per package. Designated most popular model or size.
30 mm button end blade. Flat handle.
Medicine Products: